Loading...
•
Sep 30, 2024
Longeveron Q3 2024 Earnings Report
Reported third quarter financial results and provided a business update.
Key Takeaways
Longeveron Inc. reported financial results for the quarter ended September 30, 2024, and provided a business update, highlighting the advancement of Lomecel-BTM for HLHS and mild Alzheimer’s disease.
Advanced Lomecel-BTM development for Hypoplastic Left Heart Syndrome (HLHS) and mild Alzheimer’s disease.
Achieved over 80% enrollment in the ELPIS II clinical trial for HLHS.
FDA confirmed ELPIS II is pivotal and acceptable for BLA submission for full traditional approval if positive.
CLEAR MIND Phase 2a clinical data in mild Alzheimer’s disease selected for presentation at AAIC and CTAD24.
Forward Guidance
Longeveron is focused on advancing its clinical programs and anticipates key milestones in the development of Lomecel-BTM for HLHS and Alzheimer's disease.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...